Aromatase inhibitors-based represents 36.0% of drug class demand and hospital pharmacies account for 58.0% of distribution channel sales in 2026. The breast cancer drug market was valued at USD 11.0 billion in 2025, is projected to reach USD 12.4 billion by 2036 and is forecast to post a 1.1% CAGR between 2026 and 2036.